Figure 5 Palliative-care-referral patterns

Slides:

Advertisements

Similar presentations

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Advertisements

Figure 1 Estimated annual percentages of new

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 3 Response after appearance of a new lesion

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Generations of cancer vaccine antigens

Figure 4 Management of personal care needs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Monitoring clonal evolution using liquid biopsies

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Figure 5 Identification of mucinous carcinoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 The cell cycle and the role of CDK4/6 inhibition

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Figure 4 Example of a patients with CUP

Figure 3 Care needs of patients with advanced-stage cancer

Figure 1 CAR-T-cell design

Figure 2 Examples of histopathological validation

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 1 Cost of one month of treatment with

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 1 Balance between proteasomal load and capacity

chemotherapy for patients with MC versus those with AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 2 The patterns of epithelial-to-mesenchymal

Figure 1 Translocations involved in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Variations between planned and delivered doses of radiation

Figure 3 Tumours secrete factors that cause systemic immunosuppression

Figure 2 Effect of chromosomal instability tolerance

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 2 Radiomics in cardiology

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Figure 1 Gene-expression quantification methods

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Presentation transcript:

Figure 5 Palliative-care-referral patterns Figure 5 | Palliative-care-referral patterns. a | In an oncologist-based referral model, the patient might be directed to different services and, thus, receive variable care, depending on the palliative-care expertise and referral preferences of their oncologist, as well as local supportive-care-resource availability. b | Automatic referral models streamline access to palliative care and help to standardized care through the use of routine screening and the implementation of automatic triggers for referral. The criteria for referral need to be tailored to achieve a balance between local palliative-care-resource availability and patient care needs. Hui, D. & Bruera, E. (2015) Integrating palliative care into the trajectory of cancer care Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2015.201